Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on March 15, 2023, covering events occurring on March 14, 2023. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The filing primarily details a private placement of equity securities.
Key Financial Metrics and Transaction Details
The filing reports a specific capital raise transaction rather than standard periodic financial statements (revenue, profit, or cash flow).
- Total Consideration Raised: $1,719,983.01
- Common Shares Sold: 1,550,540 shares
- Share Purchase Price: $1.10928 per share
- Warrants Issued to Investors: 775,270 warrants (50% of shares sold)
- Warrant Exercise Price: $1.04678 per share
- Warrant Terms: Exercisable after 6 months; expire 5.5 years from issuance
- Advisor Compensation: A warrant to purchase 67,611 shares issued to Laidlaw & Company (UK) Ltd. at the same exercise price and terms.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (e.g., revenue or profit changes) against prior periods. The material change reported is the entry into a Material Definitive Agreement (Securities Purchase Agreement) and the subsequent unregistered sale of equity securities to institutional and accredited investors.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the "March PIPE" (Private Investment in Public Equity) to raise capital. It notes that the securities were sold in reliance on exemptions under Section 4(a)(2) and Regulation D of the Securities Act of 1933.
Risks and Contingencies: The filing references standard representations, warranties, and covenants typical for such transactions but does not explicitly detail new operational risks or contingencies beyond the dilution inherent in the issuance of new shares and warrants.
Key Facts for Investor Verification
- Verify the actual cash proceeds received versus the stated aggregate consideration of $1.72 million.
- Confirm the dilution impact of the 1,550,540 new shares and 842,881 total warrants (investor + advisor) on existing shareholders.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions on future capital raises.
- Check subsequent filings to confirm the use of proceeds and whether the company met any performance milestones tied to the investment.